"guideline","version","file_desc","type","host","method","site","mo","rank_index","ab","disk_dose","breakpoint_S","breakpoint_R","note","sheet"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[C] Susceptibility inferred from ampicillin.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)","10 mcg","15","15","[D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","30 mcg","19","19","[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"1","1","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.125","4","[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17","[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen)","5 mcg","24","24","[B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","30 mcg","18","15",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","10 mcg","17","14",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","10 mcg","15","12",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","10 mcg","17","14",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","IP mcg","IP","IP",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","18","15",NA,"Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"16","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"16","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"8","8",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","21","21",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"8","8",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"4","4",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","20","20",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"1","1",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin",NA,"8","16",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","30 mcg","18","15",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin",NA,"4","4",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","10 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"4","4",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","10 mcg","12","12",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin",NA,"4","4",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","10 mcg","16","16",NA,"Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"4","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.06","1",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin",NA,"8","16",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","30 mcg","19","17",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","10 mcg","16","16",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"4","8",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","21","18",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","10 mcg","12","12","[B]  | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","IP mcg","IP","IP",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","18","18","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","19","19",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","17","17","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","10 mcg","12","Note","[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","4","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","16","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"Note","Note","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.03","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | [3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","16","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","10 mcg","10","Note","[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","21","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","4",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","19",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.06","0.5",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","1 unit","18","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","IP mcg","IP","IP",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",NA,"Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid",NA,"Note","Note","[A] Perform an MIC test.","Viridans group streptococci"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","16","16","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.125","1",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[3] Meropenem is the only carbapenem used for meningitis.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[C] For use in meningitis determine the meropenem MIC value. | [3] Meropenem is the only carbapenem used for meningitis.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","21","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.125","4",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2","[1] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30","[A] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin",NA,"0.06","1","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"1","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol",NA,"2","2",NA,"N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[1] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin",NA,"0.125","0.125","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",NA,"C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"1","1",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","10 mcg","23","23",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis"
"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established.","M.tuberculosis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[C] Breakpoints still under consideration.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)","10 mcg","15","15","[D] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","IP mcg","IP","IP",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[4] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24","[2] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[B]  | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note","[C]  | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note","[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","IP mcg","IP","IP","[2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2","[1] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30","[A] Breakpoints relate to topical use only.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] See table of dosages.","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",NA,"C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","30","30",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"8","8","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","10 mcg","24","24",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","S.maltophilia"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","25","25","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","Note","[C]  | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","19","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","21","21","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","23",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note","[C]  | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","16","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note","[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8","[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21","[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125","[4] The breakpoints also apply to meningitis.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125","[4] The breakpoints also apply to meningitis.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1","[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B]  | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Cefiderocol",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Doripenem",NA,"1","1",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Lefamulin",NA,"IE","IE",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes

except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem",NA,"1","1",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B]  | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE","[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and  P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B]  | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudinter-medius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.
.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.
.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","18","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)",NA,"0.03","0.03",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1","[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28","[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","20","20","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","18","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE","[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Amphotericin B",NA,"0.001","2","[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as ""S"" strains.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Amphotericin B",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Anidulafungin",NA,"0.016","0.016",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Anidulafungin",NA,"0.25","0.25",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Anidulafungin",NA,"0.03","0.03",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Anidulafungin",NA,"4","4",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Anidulafungin",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Fluconazole",NA,"Note","Note","[3] The fluconazole susceptibility of the earliest C. auris strains (likely representing the wild-type, e.g.CBS10913) was low (4 mg/L, determined in-house by EUCAST), and C. auris isolates with low azole MICs are still reported, particularly from South America. However, most C. auris isolates exhibit fluconazole MIC values >16 mg/L and harbour acquired resistance mechanisms. Due to the paucity of true wild-type, non-outbreak isolates, a fluconazole ECOFF cannot be established. Clinical data on isolates with lower MICs (≤ 16 mg/L) are very limited. Therefore, EUCAST has insufficient data to support fluconazole therapy for C. auris, even when the MIC is low.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Fluconazole",NA,"0.001","16","[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as ""S"" strains.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Fluconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Fluconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Itraconazole",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Itraconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Itraconazole",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Itraconazole",NA,"0.125","0.125",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Itraconazole",NA,"0.125","0.125",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Itraconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Micafungin",NA,"0.03","0.03",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Micafungin",NA,"0.25","0.25",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Micafungin",NA,"IE","IE","[6] MICs for C. krusei are approximately three two-fold dilution steps higher than those for C. albicans  and, similarly, those for C. guilliermondii are approximately eight two-fold dilutions higher. In addition, there were only a small number of cases involving these species in the clinical trials. This means there is insufficient evidence (IE) to indicate whether the wild-type population of these pathogens can be considered susceptible to micafungin.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Micafungin",NA,"4","4",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Micafungin",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Posaconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Posaconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Rezafungin",NA,"0.008","0.008","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Rezafungin",NA,"IE","IE","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Rezafungin",NA,"0.016","0.016","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Rezafungin",NA,"0.016","0.016","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Rezafungin",NA,"0.03","0.03","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Rezafungin",NA,"4","4","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Rezafungin",NA,"0.03","0.03","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Rezafungin",NA,"IE","IE","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Voriconazole",NA,"0.06","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Voriconazole",NA,"0.06","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Voriconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Voriconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Voriconazole",NA,"0.125","0.25",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Voriconazole",NA,"0.125","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast"
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Amphotericin B",NA,"1","1",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Amphotericin B",NA,"1","1",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Isavuconazole",NA,"0.5","0.5",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Isavuconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Itraconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus. | [4] The MIC values for isolates of A. niger and A. versicolor are in general higher than those for A. fumigatus. Whether this translates into a poorer clinical response is unknown.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Posaconazole",NA,"0.125","0.125",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Posaconazole",NA,"0.125","0.125",NA,"6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Voriconazole",NA,"1","1","[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Voriconazole",NA,"1","1","[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus "
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L.","Pseudomonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method. | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","20",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2","[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP","[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","23",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","5 mcg","Note","Note","[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","23",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25","[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14","[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[2] A provisional screen value of ≤2 mg/L can be used for antimicrobial susceptibility testing with Mycobacteria Growth Indicator Tube (MGIT, Becton Dickinson). There are insufficient MIC data with the reference method to set a clinical breakpoint.","M.tuberculosis"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
ND = No ECOFF available.","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages.
3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D]  | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum",NA,"4","4","[1] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","5 mcg","12","12","[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis "
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
ND = No ECOFF available.","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
ND = No ECOFF available.","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)",NA,"ND","ND",NA,"Topical agents"
"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin  (framycetin)","10 mcg","ND","ND",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[7] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim  (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[4] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE","[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.
4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.
4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D]  | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10","[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"0.001","4","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note","[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","22","19",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"21","21",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"1","1","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"12","12","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE","[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[3] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis "
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime  (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[7] See table of dosages for dosing for different indications.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral  (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[7] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","15","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[4] See table of dosages for dosing for different indications.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas other than  P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas other than  P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE","[1] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE","[A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE","[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge,  like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.
4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.
4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except  S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except  S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D]  | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note","[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[4] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","19","19",NA,"Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","24","24","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10","[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"0.001","4","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.
2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C]  | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note","[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","2 mcg","22","19",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","1 unit","21","21",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"1","1","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","1 unit","12","12","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE","[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note","[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note","[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[3] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B]  | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25","[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4","[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Piperacillin-tazobactam",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole",NA,"1","1","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","5 mcg","30","30","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin",NA,"1","1",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","2 mcg","21","21",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","10/10 mcg","28","28",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","2 mcg","17","17","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","5 mcg","19","19","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","1 unit","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","2 mcg","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","10/10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","10 mcg","22","22","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","5 mcg","21","21","[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","1 unit","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","10/10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","30/6 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin",NA,"4","4",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","5 mcg","14","14",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin",NA,"0.5","0.5",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","2 mcg","24","24","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","5 mcg","21","21","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin",NA,"4","4",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","2 mcg","12","12",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","10/10 mcg","22","22",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","10 mcg","28","28",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","10 mcg","24","24",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin",NA,"4","4",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","5 mcg","13","13",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole",NA,"4","4","[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","5 mcg","20","20","[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33A","33",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime",NA,"Note","Note","[3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","1 unit","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","10/10 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam",NA,"4","4","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime",NA,"Note","Note","[5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","5 mcg","24","24","[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","30 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","5 mcg","19","19",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin",NA,"0.125","0.125",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","2 mcg","33","33","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","10 mcg","28","28",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","2 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","30/6 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin",NA,"1","1",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","5 mcg","20","20",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin",NA,"0.5","0.5","[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","2 mcg","23","23","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole",NA,"2","2","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","5 mcg","25","25","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","1 unit","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","2 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","10/10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","2/1 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","30/6 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","10 mcg","40","40","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","5 mcg","19","19",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin",NA,"1","1","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","2 mcg","18","18","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole",NA,"1","1","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","5 mcg","28","28","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","10/10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","10 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","5 mcg","15","15",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin",NA,"1","1","[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","2 mcg","17","17","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole",NA,"2","2","[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","5 mcg","22","22","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","1 unit","18","18","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","2 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","10/10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","30/6 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","10 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","10 mcg","37","37","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin",NA,"0.5","0.5",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","5 mcg","21","21",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","2 mcg","15","15","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","5 mcg","19","19","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","18","18","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C]  | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B]  | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp.

except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis "
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] For bedaquiline, breakpoints were determined using the EUCAST reference method.","M.tuberculosis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination.
3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods.","M.tuberculosis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination.
3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods. | [4] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin  (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin  (framycetin)",NA,"8","8",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin  (framycetin)","10 mcg","12","12",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin  (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin  (framycetin)",NA,"1","1",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin  (framycetin)","10 mcg","14","14",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin  (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin  (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid  (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents"
"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents"